Abstract: The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.

Abstract: The present invention relates to a compound decreasing the concentration of 2-hydroxy-glutarate (2HG) in a subject for use in treating, preventing, and/or preventing progression of cardiac remodeling, in particular cardiomyopathy and/or heart failure and to viral particles, compositions, uses and methods related thereto.

Abstract: The present invention relates to microcapsules comprising a core containing vitamin B3, which are characterised by a coating layer system comprising two layers of shellac and a pH-modulating substance provided between the two layers of shellac.

Abstract: The invention relates to novel pyrido-phenanthroline derivatives, to the production and use thereof in the field of medicine, in particular for cancer therapy.

Abstract: The present invention relates to a method for the preparation of a metal-organic framework structure compound, the metal-organic framework structure compound being prepared such as well as the use of the metal-organic framework structure compound being prepared such as adsorbent.

Abstract: The invention relates to a porous hydrogel matrix having substantially interconnected tunnel-shaped micropores with a three-dimensional configuration of an interconnected hollow tetrapod network. Such matrices may be used to entrap motile cells that migrate into the micropores of said matrix. The matrices of the invention are formed by a method comprising the steps of providing a solution of a hydrogel-forming material, providing a template material with a three-dimensional configuration corresponding to the negative configuration of the desired interconnected porous structure of the hydrogel material, said template material comprising interconnected zinc oxide tetrapod (t-ZnO) networks, casting the solution of hydrogel-forming material onto the template and removing the template material from the hydrogel material by acid hydrolysis of the template material.

Abstract: The present invention generally relates to the field of antimicrobial peptides (AMPs), and more specifically to cationic intrinsically disordered antimicrobial peptides (CIDAMPs) and their use as disinfectants and therapeutic agents for the treatment of infections, especially as a therapeutic alternative for the treatment of infectious diseases caused by antibiotic resistant microorganisms.

Abstract: There is provided a process for preparing a zirconium-based metal organic framework (Zr-MOF), the process comprising the steps (i) preparing a reaction mixture comprising zirconium ions, sulfate ions and at least one organic linker compound in an aqueous solvent; and (ii) heating the reaction mixture from step (i).

Abstract: The present invention relates to microcapsules comprising a core containing an active substance, which are characterised by a coating layer system comprising two layers of shellac and a pH-modulating substance provided between the two layers of shellac.

Abstract: The invention relates to oseltamivir derivatives as influenza neuraminidase inhibitors for treating influenza infections and to a method for producing said compounds.

Abstract: Photosensitive molecular switch, having a chelate ligand, a metal ion bonded coordinatively to the chelate ligand, the metal ion being selected from the group of metal ions consisting of Mn2+, Mn3+, Fe2+, Fe3+, Co2+ and Ni2+, a photochromic system which is bonded covalently to the chelate ligand and can be isomerized by irradiation, this system being bonded coordinatively to the metal ion in one configuration and not bonded to the metal ion in the other configuration.

Abstract: The present invention relates generally to a method of increasing lipid oxidation in a mammal and to agents useful for same. More particularly, the present invention relates to a method of increasing lipid oxidation in a mammal by administering a ligand which interacts with the IL-6 receptor and signals via interaction with a gp130/LIF receptor heterodimer. In a related aspect, the present invention provides a method of increasing insulin sensitivity in a mammal. The method of present invention is useful, inter alia, in the treatment and/or prophylaxis of conditions characterized by unwanted lipid accumulation (such as obesity, obesity induced-metabolic disorders, type II diabetes, dyslipidemia, glucose intolerance, insulin resistance, obstructive sleep apnea, cardiovascular disease or non-alcoholic fatty liver disease) or inadequate insulin sensitivity.

Abstract: Provided are methods and compositions for the detection, prevention and treatment of primary and metastatic neoplastic diseases, including, but not limited to, human carcinomas, in particular head and neck squamous cell carcinoma. In particular, an antibody and antigen-binding fragment as well as variants thereof are provided that bind to an epitope of LOXL4 in the cytoplasm and/or on the cell surface of tumor cells, which are useful in the diagnosis and especially the treatment of a tumor which expresses LOXL4.

Abstract: The present invention relates to physically-chemically and pharmacokinetically enhanced N?-hydroxy-L-arginine (NOHA) derivatives and a method for producing the NOHA derivatives having enhanced physical-chemical and pharmacokinetic properties according to the invention.

Abstract: Nucleic acid molecule selected from the group consisting of (a) a nucleic acid molecule having a nucleotide sequence shown in SEQ ID: NO 1, (b) a nucleic acid molecule which encodes a peptide having an amino acid sequence shown in SEQ ID: NO 2, (c) a nucleic acid molecule whose complementary strand hybridizes to a nucleic acid molecule according to (a) or (b) and which codes for a peptide which binds to ciliary neurotrophic factor receptor (CNTFR), the peptide binding with lower affinity than ciliary neurotrophic factor to the interleukin-6 receptor (IL-6R), (d) a nucleic acid molecule whose nucleotide sequence differs from the nucleotide sequence of a nucleic acid molecule according to (c) due to the degenerated genetic code, the codon at positions 82-84 of the nucleic acid molecule according to (a) coding for a non-positively charged amino acid, and the peptide at position 28 shown in SEQ ID: NO 2 having a non-positively charged amino acid residue.

Abstract: The disclosure relates to a method for reconstructing the source of an electromagnetic field. Firstly, a measurement space separate from the source is selected so that the measurement space is connected to the source via a magnetically homogeneous spatial region. Measured values of the electromagnetic field emitted by the source are recorded on the surface of the measurement space so that the electromagnetic field in the measurement space can be uniquely determined in the context of an error bound determined by the discreteness of the measured values. A mathematical model of the electromagnetic source is developed which has a multiplicity of unknowns, and a system of equations is set up that relates the unknowns of the model to the measured values. The system of equations is solved in order to determine the characteristics of the electromagnetic source. The disclosure also relates to an arrangement for carrying out the method.

Abstract: A measuring method and device for characterizing a semiconductor component (1) having a pn junction and a measuring surface, which has a contacting subarea, covered by a metallization. The method including: A. Planar application of electromagnetic excitation radiation onto the measuring area of the semiconductor component (1) for separating charge carrier pairs in the semiconductor component (1), and B. spatially resolved measurement of electromagnetic radiation originating from the semiconductor component (1) using a detection unit. In one step A, a predetermined excitation subarea of the measuring surface has a predetermined intensity of the excitation radiation and at least one sink subarea of the measuring surface has an intensity of the excitation radiation which is less than the intensity applied to the excitation subarea. The excitation and sink subareas are disposed on opposite sides of said contacting subarea and adjoin it and/or entirely or partially overlap it.

Abstract: Nucleic acid molecule selected from the group consisting of (a) a nucleic acid molecule having a nucleotide sequence shown in SEQ ID: NO 1, (b) a nucleic acid molecule which encodes a peptide having an amino acid sequence shown in SEQ ID: NO 2, (c) a nucleic acid molecule whose complementary strand hybridizes to a nucleic acid molecule according to (a) or (b) and which codes for a peptide which binds to ciliary neurotrophic factor receptor (CNTFR), the peptide binding with lower affinity than ciliary neurotrophic factor to the interleukin-6 receptor (IL-6R), (d) a nucleic acid molecule whose nucleotide sequence differs from the nucleotide sequence of a nucleic acid molecule according to (c) due to the degenerated genetic code, the codon at positions 82-84 of the nucleic acid molecule according to (a) coding for a non-positively charged amino acid, and the peptide at position 28 shown in SEQ ID: NO 2 having a non-positively charged amino acid residue.

Abstract: The present invention relates generally to a method of increasing lipid oxidation in a mammal and to agents useful for same. More particularly, the present invention relates to a method of increasing lipid oxidation in a mammal by administering a ligand which interacts with the IL-6 receptor and signals via interaction with a gp130/LIF receptor heterodimer. In a related aspect, the present invention provides a method of increasing insulin sensitivity in a mammal. The method of present invention is useful, inter alia, in the treatment and/or prophylaxis of conditions characterised by unwanted lipid accumulation (such as obesity, obesity induced-metabolic disorders, type II diabetes, dyslipidemia, glucose intolerance, insulin resistance, obstructive sleep apnea, cardiovascular disease or non-alcoholic fatty liver disease) or inadequate insulin sensitivity.

Abstract: A magnetostrictive layer system is suggested comprising at least one layer sequence comprising an anti-ferromagnetic, (AFM), layer and a magnetostrictive, ferromagnetic, FM, layer arranged directly thereon, wherein the layer sequence has an associated exchange bias, EB, field, the EB-induced degree of magnetization of the FM layer in the absence of an external magnetic field being within a range between 85% and 100%, and the angle ?opt, which is enclosed by the EB field direction and the magnetostriction direction, that has the maximum piezomagnetic coefficient in the absence of an external magnetic field, within a plane parallel to the AFM layer and the FM layer lies within a range between 10° and 80°.